Vimarsana
Biggest News Aggregation in the World

Page 3 - Exact Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exact Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exact Science Today - Breaking & Trending Today

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study - Vimarsana News

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included...

Study: New Cologuard finds more cancer, fewer false alarms - Vimarsana News

Study: New Cologuard finds more cancer, fewer false alarms

The new test detected 94% of cancers and was 91% accurate in determining who didn’t have cancer, up from 92% cancer sensitivity and 87% specificity for the original Cologuard.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States - Vimarsana News

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

MADISON, Wis.--(BUSINESS WIRE)--Feb 28, 2024--

Exact Sciences Launches Riskguard Hereditary Cancer Test in the United States - Vimarsana News

Exact Sciences Launches Riskguard Hereditary Cancer Test in the United States

28.02.2024 - Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes ... Seite 1

Leerink Partnrs Brokers Boost Earnings Estimates for Exact Sciences Co. (NASDAQ:EXAS) - Vimarsana News

Leerink Partnrs Brokers Boost Earnings Estimates for Exact Sciences Co. (NASDAQ:EXAS)

Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Investment analysts at Leerink Partnrs boosted their Q1 2024 EPS estimates for Exact Sciences in a research note issued to investors on Wednesday, February 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn ($0.36) per share for the quarter, up from […]